Syndivia Unveils New GeminiMab Site-Specific Conjugation Technology at World ADC London 2024

STRASBOURG (France) – March 14, 2024 – Syndivia is pleased to officially unveil GeminiMab, our next-generation hinge site-specific conjugation platform, at World ADC London 2024.

This new technology enables the creation of DAR1 and other low-DAR ADCs with improved stability, enhanced tumor penetration, and high-dose clinical potential. GeminiMab represents a major step forward for scalable, native IgG conjugation and sets the stage for a new class of ADCs optimized for therapeutic index.

Visitors to the conference are invited to explore the details in our poster #45, where we present the first public data on the platform. And of course, feel free to stop by and discuss – our team is always happy to exchange ideas with fellow ADC enthusiasts.

Syndivia continues to push the boundaries of ADC innovation, and we look forward to sharing more as the GeminiMab pipeline advances.